86.55
-1.65(-1.87%)
Currency In USD
Address
25 West Watkins Mill Road
Redwood City, MD 20878
United States of America
Phone
240 327 0603
Website
Sector
Healthcare
Industry
Biotechnology
Employees
163
First IPO Date
February 04, 2022
| Name | Title | Pay | Year Born |
| Mr. Rami Elghandour | Chairman of the Board, Chief Executive Officer & President | 1.21M | 1979 |
| Mr. Neeraj P. Teotia | Chief Commercial Officer | 461,949 | 1975 |
| Ms. Michelle Lim Gilson | Chief Financial Officer | 785,992 | 1993 |
| Dr. Christopher R. Heery M.D. | Chief Medical Officer | 794,520 | 1980 |
| Ms. Kate Aiken | Chief People Officer | 0 | N/A |
| Ms. Maryam Abdul-Kareem J.D., M.S. | General Counsel & Chief Legal Officer | 0 | N/A |
| Ms. Aileen Fernandes | Chief Business Officer | 0 | N/A |
| Mr. Narinderjeet Singh M.S. | Chief Technical Officer | 0 | 1972 |
| Ms. Myesha Lacy | Chief Investor & Communications Officer | 0 | N/A |
| Dr. Heba Nowyhed Ph.D. | Chief Scientific Officer | 0 | N/A |
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.